Pfizer's Albert Bourla told investors that major drugmakers are "ready to roll up their sleeves" and build out more direct-to ...

As investors and industry watchers juggle the twin possibilities of pharmaceutical import tariffs and potential drug pricing ...

Pharmaceutical stocks slumped after President Donald Trump sent letters to 17 drugmakers with an ultimatum to reduce drug ...

President Trump escalated pressure on the pharmaceutical industry last week by sending letters to 17 major drug companies ...

PFE eyes Q2 earnings beat as strength in Vyndaqel and Padcev is expected to offset declines from Eliquis, Ibrance and Prevnar ...

Discover Bristol-Myers Squibb's Q2 2025 earnings insights: 17% growth, new partnerships, and raised guidance signal strong performance and a ...

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID headwinds. See why PFE stock is a buy.

Pharma’s next big leap won’t come from the lab. It’ll come from outside the lab, where the rules of narrative, attention, and ...

These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.

The Swiss drugmaker discussed the option of selling drugs directly to patients with U.S. officials following Trump administration calls for the industry to cut prices.

Roche also announced it was weighing direct-to-patient drug sales in the U.S., bypassing middlemen for some of its pricey medicines ...